Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Under Pressure To Spend On M&A

Company Has $6.7bn In Cash

Executive Summary

The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development

You may also be interested in...



Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology

Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.

Vertex Suffers Setback In Its Search For Post-CF Blockbusters

Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.

Best-In-Class In MASH? Boehringer’s Hopes Raised By Glucagon/GLP-1 Phase II Results

The results could help BI and Zealand Pharma challenge in the MASH field, though analysts are wary of claims around fibrosis improvement.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel